An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer

Published:November 11, 2017DOI:


      • Molecular classification of endometrioid endometrial cancers identifies cases at increased risk for recurrence.
      • Women whose tumors have copy number alterations have reduced progression-free and cancer-specific survival.
      • ~8% of endometrioid endometrial cancers are copy number altered, the majority of which are low grade, low stage cases.



      The purpose of this study was to assess the prognostic significance of a simplified, clinically accessible classification system for endometrioid endometrial cancers combining Lynch syndrome screening and molecular risk stratification.


      Tumors from NRG/GOG GOG210 were evaluated for mismatch repair defects (MSI, MMR IHC, and MLH1 methylation), POLE mutations, and loss of heterozygosity. TP53 was evaluated in a subset of cases. Tumors were assigned to four molecular classes. Relationships between molecular classes and clinicopathologic variables were assessed using contingency tests and Cox proportional methods.


      Molecular classification was successful for 982 tumors. Based on the NCI consensus MSI panel assessing MSI and loss of heterozygosity combined with POLE testing, 49% of tumors were classified copy number stable (CNS), 39% MMR deficient, 8% copy number altered (CNA) and 4% POLE mutant. Cancer-specific mortality occurred in 5% of patients with CNS tumors; 2.6% with POLE tumors; 7.6% with MMR deficient tumors and 19% with CNA tumors. The CNA group had worse progression-free (HR 2.31, 95%CI 1.53–3.49) and cancer-specific survival (HR 3.95; 95%CI 2.10–7.44). The POLE group had improved outcomes, but the differences were not statistically significant. CNA class remained significant for cancer-specific survival (HR 2.11; 95%CI 1.04–4.26) in multivariable analysis. The CNA molecular class was associated with TP53 mutation and expression status.


      A simple molecular classification for endometrioid endometrial cancers that can be easily combined with Lynch syndrome screening provides important prognostic information. These findings support prospective clinical validation and further studies on the predictive value of a simplified molecular classification system.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Morice P.
        • Leary A.
        • Creutzberg C.
        • Abu-Rustum N.
        • Darai E.
        Endometrial cancer.
        Lancet. 2016; 387: 1094-1108
        • Provenzale D.
        • Gupta S.
        • Ahnen D.J.
        • Bray T.
        • Cannon J.A.
        • Cooper G.
        • et al.
        Genetic/familial high-risk assessment: colorectal version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
        J. Natl. Compr. Cancer Netw. 2016; 14: 1010-1030
        • Kandoth C.
        • Schultz N.
        • Cherniack A.D.
        • Akbani R.
        • Liu Y.
        • Shen H.
        • et al.
        Integrated genomic characterization of endometrial carcinoma.
        Nature. 2013; 497: 67-73
        • Talhouk A.
        • McConechy M.K.
        • Leung S.
        • Li-Chang H.H.
        • Kwon J.S.
        • Melnyk N.
        • et al.
        A clinically applicable molecular-based classification for endometrial cancers.
        Br. J. Cancer. 2015; 113: 299-310
        • Talhouk A.
        • McConechy M.K.
        • Leung S.
        • Yang W.
        • Lum A.
        • Senz J.
        • et al.
        Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer.
        Cancer. 2017; 123: 802-813
        • Talhouk A.
        • McAlpine J.N.
        New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care.
        Gynecol. Oncol. Res. Pract. 2016; 3: 14
        • Maxwell G.L.
        • Mutch D.G.
        The promise of molecular staging for the future.
        Cancer. 2017; 123: 728-730
        • Brinton L.A.
        • Felix A.S.
        • McMeekin D.S.
        • Creasman W.T.
        • Sherman M.E.
        • Mutch D.
        • et al.
        Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.
        Gynecol. Oncol. 2013; 129: 277-284
        • Goodfellow P.J.
        • Billingsley C.C.
        • Lankes H.A.
        • Ali S.
        • Cohn D.E.
        • Broaddus R.J.
        • et al.
        Combined microsatellite instability, MLH1 methylation analysis, and immunohistochemistry for Lynch syndrome screening in endometrial cancers from GOG210: an NRG Oncology and Gynecologic Oncology Group study.
        J. Clin. Oncol. 2015; 33: 4301-4308
        • Billingsley C.C.
        • Cohn D.E.
        • Mutch D.G.
        • Stephens J.A.
        • Suarez A.A.
        • Goodfellow P.J.
        Polymerase varepsilon (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
        Cancer. 2015; 121: 386-394
        • Boland C.R.
        • Thibodeau S.N.
        • Hamilton S.R.
        • Sidransky D.
        • Eshleman J.R.
        • Burt R.W.
        • et al.
        A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.
        Cancer Res. 1998; 58: 5248-5257
        • McMeekin D.S.
        • Tritchler D.L.
        • Cohn D.E.
        • Mutch D.G.
        • Lankes H.A.
        • Geller M.A.
        • et al.
        Clinicopathologic significance of mismatch repair defects in endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.
        J. Clin. Oncol. 2016; 34: 3062-3068
        • Cox D.
        Regression models and life tables.
        JR Stat. Soc. B. 1972; 34: 187-220
        • Team RC
        R: A language and environment for statistical computing.
        R Foundation for Statistical Computing, Vienna, Austria2013
        • Church D.N.
        • Stelloo E.
        • Nout R.A.
        • Valtcheva N.
        • Depreeuw J.
        • Ter Haar N.
        • et al.
        Prognostic significance of POLE proofreading mutations in endometrial cancer.
        J. Natl. Cancer Inst. 2015; 107
        • Haraldsdottir S.
        • Hampel H.
        • Tomsic J.
        • Frankel W.L.
        • Pearlman R.
        • de la Chapelle A.
        • et al.
        Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations.
        Gastroenterology. 2014; 147 (e1301): 1308-1316
        • Setiawan V.W.
        • Yang H.P.
        • Pike M.C.
        • McCann S.E.
        • Yu H.
        • Xiang Y.B.
        • et al.
        Type I and II endometrial cancers: have they different risk factors?.
        J. Clin. Oncol. 2013; 31: 2607-2618
        • Creasman W.T.
        • Odicino F.
        • Maisonneuve P.
        • Quinn M.A.
        • Beller U.
        • Benedet J.L.
        • et al.
        Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer.
        Int. J. Gynaecol. Obstet. 2006; 95: S105-143
        • Dunican D.S.
        • McWilliam P.
        • Tighe O.
        • Parle-McDermott A.
        • Croke D.T.
        Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization.
        Oncogene. 2002; 21: 3253-3257
        • Sinicrope F.A.
        DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer.
        Nat. Rev. Clin. Oncol. 2010; 7: 174-177
        • Webber E.M.
        • Kauffman T.L.
        • O'Connor E.
        • Goddard K.A.
        Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy.
        BMC Cancer. 2015; 15: 156
        • Chen Z.
        • Liu Z.
        • Li W.
        • Qu K.
        • Deng X.
        • Varma M.G.
        • et al.
        Chromosomal copy number alterations are associated with tumor response to chemoradiation in locally advanced rectal cancer.
        Genes Chromosomes Cancer. 2011; 50: 689-699
        • de Rosa N.
        • Rodriguez-Bigas M.A.
        • Chang G.J.
        • Veerapong J.
        • Borras E.
        • Krishnan S.
        • et al.
        DNA mismatch repair deficiency in rectal cancer: benchmarking its impact on prognosis, neoadjuvant response prediction, and clinical cancer genetics.
        J. Clin. Oncol. 2016; 34: 3039-3046
        • Murnyak B.
        • Hortobagyi T.
        Immunohistochemical correlates of TP53 somatic mutations in cancer.
        Oncotarget. 2016; 7: 64910-64920
        • Watkins J.A.
        • Irshad S.
        • Grigoriadis A.
        • Tutt A.N.
        Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
        Breast Cancer Res. 2014; 16: 211
        • Marquard A.M.
        • Eklund A.C.
        • Joshi T.
        • Krzystanek M.
        • Favero F.
        • Wang Z.C.
        • et al.
        Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs.
        Biomark. Res. 2015; 3: 9
        • Ledermann J.A.
        • Drew Y.
        • Kristeleit R.S.
        Homologous recombination deficiency and ovarian cancer.
        Eur. J. Cancer. 2016; 60: 49-58
        • Abkevich V.
        • Timms K.M.
        • Hennessy B.T.
        • Potter J.
        • Carey M.S.
        • Meyer L.A.
        • et al.
        Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
        Br. J. Cancer. 2012; 107: 1776-1782
        • Moore K.N.
        • Fader A.N.
        Uterine papillary serous carcinoma.
        Clin. Obstet. Gynecol. 2011; 54: 278-291
        • Schultheis A.M.
        • Martelotto L.G.
        • De Filippo M.R.
        • Piscuglio S.
        • Ng C.K.
        • Hussein Y.R.
        • et al.
        TP53 mutational spectrum in endometrioid and serous endometrial cancers.
        Int. J. Gynecol. Pathol. 2016; 35: 289-300
        • O'Hara A.J.
        • Bell D.W.
        The genomics and genetics of endometrial cancer.
        Adv. Genomics Genet. 2012; 2012: 33-47
        • McConechy M.K.
        • Ding J.
        • Cheang M.C.
        • Wiegand K.
        • Senz J.
        • Tone A.
        • et al.
        Use of mutation profiles to refine the classification of endometrial carcinomas.
        J. Pathol. 2012; 228: 20-30
        • Stelloo E.
        • Nout R.A.
        • Osse E.M.
        • Jurgenliemk-Schulz I.J.
        • Jobsen J.J.
        • Lutgens L.C.
        • et al.
        Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts.
        Clin. Cancer Res. 2016; 22: 4215-4224
        • Creutzberg C.L.
        • van Putten W.L.
        • Koper P.C.
        • Lybeert M.L.
        • Jobsen J.J.
        • Warlam-Rodenhuis C.C.
        • et al.
        Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma.
        Lancet. 2000; 355: 1404-1411
        • Nout R.A.
        • Smit V.T.
        • Putter H.
        • Jürgenliemk-Schulz I.M.
        • Jobsen J.J.
        • Lutgens L.C.
        • et al.
        Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
        Lancet. 2010; 375: 816-823
        • Cerami E.
        • Gao J.
        • Dogrusoz U.
        • Gross B.E.
        • Sumer S.O.
        • Aksoy B.A.
        • et al.
        The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
        Cancer Discov. 2012; 2: 401-404
        • Gao J.
        • Aksoy B.A.
        • Dogrusoz U.
        • Dresdner G.
        • Gross B.
        • Sumer S.O.
        • et al.
        Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
        Sci. Signal. 2013; 6: pl1